Literature DB >> 407795

Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors.

D A Eschenbach, J P Harnisch, K K Holmes.   

Abstract

In a case-control study of matched pairs, the risk of acute pelvic inflammatory disease (PID) was 4.4 times higher in intrauterine contraceptive device (IUD) users than in nonusers (p less than 0.001). Of approximately 500,000 cases of acute PID occurring annually in the United States, an estimated 110,000 are attributable to IUD's, costing over forty-four million dollars per year. PID was attributable to the IUD in 77 per cent of IUD users. No particular type of IUD was implicated. The relative risk of acute PID in IUD users over nonusers was higher in nulligravid women than in previously pregnant women and was directly related to socioeconomic status (SES), but the total annual risk of PID in IUD users appear inversely related to SES. IUD use significantly increased the risk of nongonococcal PID. Fever occurred in 13 (21 per cent) of 61 IUD users and 59 (41 per cent) of 143 nonusers (p less than 0.025). Among women with nongonococcal PID, and adnexal mass greater than or equal to 6 cm. was noted in 14 (40 per cent) of 35 IUD users and in only 12 (15 per cent) of 78 nonusers (p less than 0.01). An increased risk of gonococcal PID was found among non-Caucasians and women not using contraception, while the risk of nongonococcal PID was increased among women with a past history of gonorrhea. Oral contraceptive use may protect women with gonorrhea from developing PID. Menstruation precipitates the onset of symptoms of gonococcal PID.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 407795     DOI: 10.1016/0002-9378(77)90051-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  21 in total

Review 1.  Pelvic inflammatory disease epidemiology: what do we know and what do we need to know?

Authors:  I Simms; J M Stephenson
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

Review 2.  Vaginal douching: evidence for risks or benefits to women's health.

Authors:  Jenny L Martino; Sten H Vermund
Journal:  Epidemiol Rev       Date:  2002       Impact factor: 6.222

Review 3.  Vaginal douching as a possible risk factor for pelvic inflammatory disease.

Authors:  K A Forrest; A E Washington; J R Daling; R L Sweet
Journal:  J Natl Med Assoc       Date:  1989-02       Impact factor: 1.798

4.  Use of heme compounds as iron sources by pathogenic neisseriae requires the product of the hemO gene.

Authors:  W Zhu; D J Hunt; A R Richardson; I Stojiljkovic
Journal:  J Bacteriol       Date:  2000-01       Impact factor: 3.490

5.  The relation between serum sex steroid levels and plasma cell infiltrates in endometritis.

Authors:  R Punnonen; M Lehtinen; K Teisala; R Aine; I Rantala; P K Heinonen; A Miettinen; S Laine; J Paavonen
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

6.  Comparison of clinical and epidemiological characteristics of pelvic inflammatory disease classified by endocervical cultures of Neisseria gonorrhoeae and Chlamydia trachomatis.

Authors:  F N Judson; B G Tavelli
Journal:  Genitourin Med       Date:  1986-08

7.  Bacterial colonization of intrauterine devices (IUDs).

Authors:  A S Wolf; D Krieger
Journal:  Arch Gynecol       Date:  1986

Review 8.  Pelvic inflammatory disease: current concepts and treatment guidelines.

Authors:  P A Dale; P A Rice; K C Edelin
Journal:  J Gen Intern Med       Date:  1986 Nov-Dec       Impact factor: 5.128

Review 9.  Tubo-ovarian abscess: pathogenesis and management.

Authors:  N G Osborne
Journal:  J Natl Med Assoc       Date:  1986-10       Impact factor: 1.798

10.  Antibodies to opacity proteins (Opa) correlate with a reduced risk of gonococcal salpingitis.

Authors:  F A Plummer; H Chubb; J N Simonsen; M Bosire; L Slaney; N J Nagelkerke; I Maclean; J O Ndinya-Achola; P Waiyaki; R C Brunham
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.